Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immune Checkpoint, ADC, and Next-Generation Modality Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for B7-H3/CD276 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | B7-H3 (CD276) ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CD276 Products |
| Gene Delivery | CD276 Full-Length ORF Lentivirus For stable cell line construction in CHO/HEK293 cells. Preserves native conformation. |
View CD276 Products |
| Benchmark Ab | Anti-B7-H3 (Vobramitamab / Ifinatamab Biosimilar) Sequence-matched positive control for binding/blocking assays. |
View CD276 Products |
| Validator | CD276 siRNA Set For knockdown specificity verification in cell-based assays. |
View CD276 Products |
| Related Target A | PD-L1 (CD274) Checkpoint synergy for combination therapy strategies |
View CD274 Products |
| Related Target B | B7-H4 (VTCN1) Related B7 family member for selectivity screening |
View VTCN1 Products |
| Related Target C | CD3E T-cell engager component for bispecific antibody development |
View CD3E Products |
| Related Target D | 4-1BB (CD137) Co-stimulatory target for B7-H3 x 4-1BB bispecific immune agonists |
View 4-1BB Products |
Critical Assay Challenges & TarMart Technical Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation for preclinical safety | Human/Mouse/Cyno CD276 ortholog proteins available with >95% purity, sequence verified by mass spec, HEK293 expressed for native glycosylation. |
| ADC Internalization efficiency quantification | High-purity ECD-Fc (IgV-IgC-IgV-IgC domain) preserves structural epitopes for internalization kinetics. Theoretical MW confirmed. |
| B7 family selectivity (Off-target avoidance) | Homolog panel proteins (B7-H4, PD-L1, B7-H6) strictly verified by mass spec for counter-screening. |
| Lack of Reliable Clinical Controls | Clinical Benchmark Antibodies (Vobramitamab, Enoblituzumab, Omburtamab, Ifinatamab sequences) included with Endotoxin <1EU/ug. |
| False Positives in Cell Binding Assays | Validated CD276 siRNA included for specificity checks and target engagement confirmation. |
Live B7-H3/CD276 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for B7-H3 therapeutics is intensifying, with major players shifting focus from traditional naked mAbs to Antibody-Drug Conjugates (ADCs) and T-cell engagers. B7-H3 (CD276) is a premier tumor-associated antigen due to its restricted expression in normal tissues yet high overexpression across a wide range of solid tumors including small cell lung cancer (SCLC), metastatic castration-resistant prostate cancer (mCRPC), neuroblastoma, and head/neck cancers. Pipeline leaders include MacroGenics (vobramitamab duocarmazine MGC018 in Phase II/III), Daiichi Sankyo (ifinatamab deruxtecan DS-7300 in Phase II/III), Merck (enoblituzumab Fc-enhanced mAb, omburtamab radio-conjugate), Y-mAbs (omburtamab for pediatric CNS tumors), and BioNTech/Fate Therapeutics (CAR-T/CAR-NK). The dominant modality is ADC (~65% of pipeline), followed by T-cell engagers and CAR-T. Future R&D directions include overcoming bystander toxicity and drug resistance, combining with PD-1/PD-L1 checkpoint inhibitors, and expanding to pediatric indications. Bispecific formats such as B7-H3 x CD3 and B7-H3 x 4-1BB are also emerging to achieve localized T-cell activation while minimizing systemic cytokine release.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Daiichi Sankyo, MacroGenics | SCLC, mCRPC, Prostate Cancer | Internalization Assay (Need high-purity ECD-Fc with intact IgV-IgC domains) |
| Bispecific / T-Cell Engager | MacroGenics, Genmab, Merck | Solid Tumors | Heterodimer Validation (Need cross-reactive Abs and precise ECD forms) |
| mAb (Fc-enhanced) | Merck (Enoblituzumab) | Prostate, Head/Neck | ADCC/CDC Reporter Assay (Need stable CD276+ cell lines via Lentivirus) |
| CAR-T / CAR-NK | City of Hope, BMS, Fate Therapeutics | Pediatric CNS, Refractory Solid Cancers | Cell Binding Validation (Need full-length CD276 Lentivirus for transduction) |